Assessing Disease Progression in MS Treatment

Slides:

Advertisements

Similar presentations

Four Known Types of MS Clinically isolated syndrome (CIS)

Advertisements

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Multiple sclerosis: Oral Therapies and Beyond

CORRELATION OF BIOMARKERS FOR AXONAL DEGENERATION WITH RETINAL NERVE FIBER LAYER THICKNESS AND DISABILITY IN DIFFERENT PHASES OF MULTIPLE SCLEROSIS UZUNKOPRU.

MRI contrast-enhancement and progression of X-ALD

Discovery set: 10 RRMS (2) vs 9 SPMS (3)

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Latest Advances in HCM.

IL-12 and IL-23.

Highlights From the 2017 Annual European MS Meeting

Starting Strong: Initial Evaluation of the Patient With HCV

MS Highlights From the 2017 Annual Neurology Meeting

MR Imaging in Children.

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Glaucoma Progression.

The ABCs of AF.

Nat. Rev. Neurol. doi: /nrneurol

What Predicts Disability Progression in Multiple Sclerosis?

Charting Progress in MS Diagnosis and Treatment for Today and Tomorrow

Overall Program Goals. Overall Program Goals Current Approaches.

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

The ABCs of Nitric Oxide in the Skin

Challenges in Managing Progressive Multiple Sclerosis

Addressing Disease Burden in Asthma

Novel Therapies for the Treatment of MS

Dispelling Myths and Misconceptions ACC/AHA 2013 Digoxin Guidelines for Heart Failure.

Are We Closer to Personalized Medicine in MS?

Management Challenges in CLL

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

The Biology Behind BCL2 as a Target in Myeloma

Is RA Treatment Addressing the Real Needs of Patients?

Charting Progress in MS Treatment:

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Advancing the Treatment of IBD With Biologics

Treating to Target in MS

Using Heart Rate as a Biomarker in Clinical Practice.

In-Depth Discussion of Key Data on Immunotherapy for Allergic Diseases

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Management of Systematic Lupus Erythematosus

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Maintenance Therapy in Advanced Ovarian Cancer

What's New in Therapeutic Options for Moderate to Severe RA?

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Imaging in Liver Malignancy

Treatment-Resistant Schizophrenia

Clinical Pearls on Hot Topics in MS

Figure 1 Biomarkers associated with different clinical phases in MS

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Gadolinium Update.

Clinical Challenges and Updates in Managing Seizure Clusters

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

The ABCs of AF.

Selecting Treatment Approaches in Hemophilia

Novel Therapeutics in MS

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

PAH Pathways: What Do the Data Tell Us?”

Evaluating Success of Current Treatments for HCM

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Updates in Progressive MS

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

The Building Blocks of Homocystinuria and Homocysteinemia Management

Figure 2 Clinical data and variation of sNfL levels of patients 4–6 with ATZ-treated MS Clinical data and variation of sNfL levels of patients 4–6 with.

What's New in Rare CKDs?.

Understanding the Role of Disability in MS Management

Selective Immunomodulation in MS

Presentation transcript:

Assessing Disease Progression in MS Treatment

Program Goals

Biomarkers in MS

Limitations of Clinical and MRI Assessments

Clinical Use of Markers of Progression in RRMS

Characteristics of Ideal Biomarkers

Lymphocytosis and Lymphocyte Profile

OCT

CSF Markers of Inflammation

Limitations of CSF Markers of Inflammation

Molecular Imaging

Neurofilament Levels as Markers of Disease Activity

NfL Levels as Markers of Therapeutic Response

NfL as a Marker of Therapeutic Response: Summary

Limitations of Serum NfL Assessment in Clinical Practice

Metabolic Imaging

Limitations of Clinical Assessments of Progression

Leptomeningeal Contrast Enhancement

Safety of Repeated Gd-Enhanced MRI

Kynurenine Pathway in Progression to SPMS

Challenges in Assessing Therapeutic Response in SPMS

The Need for Different Imaging Markers for PPMS

Conclusions

Abbreviations

Abbreviations (cont)